Abstract:Computational drug discovery methods have been used in this study to identify potential inhibitors for Pantothenate Synthetase, a crucial enzyme for mycobacterial survival. Four compounds, CID2813602, 24357538, CID753354, and CID4798023, have shown strong binding energies and stable interactions with the target protein. These compounds hold promise for the development of new treatments targeting drug‐resistant TB strains. Antibiotics have played a crucial role in significantly reducing the incidence of tuberculosis (TB) infection worldwide. Even before the mid‐20th century, the mortality rate of TB onset within five years was around 50 %. So, the introduction of antibiotics has changed the scenario of TB from a serious threat to a manageable one. However, the emergence of resistance to anti‐TB drugs poses a significant challenge. So, to overcome this situation the therapeutic approaches and drug targets need to be reformed. This study focused on finding potential inhibitors by targeting Pantothenate Synthetase, a crucial enzyme for Mycobacterium tuberculosis (Mtb) survival, through computational drug discovery methods. Molecular docking and virtual screening were employed to identify potential inhibitors from Diverse‐lib. Four compounds, namely CID2813602, 24357538, CID753354, and CID4798023, exhibited strong binding energies and stable interaction with the target protein. Further assessment of these compounds through MD simulation and Post MD simulation showed significant dynamic stability. The minimum energy transition calculated using the free energy landscape analysis of these compounds when docked with Pantothenate Synthetase confirmed the stability of each complex due to its minimum energy production. The free binding energy calculation of each complex also showed the intramolecular interaction contributes to the strong binding affinity of the compounds within the enzyme's active site clarifying their mechanisms of action. This research showcases the effectiveness of computational methods in promptly identifying potential anti‐TB drugs, paving the way for future experimental validation and optimization. It holds promise for the development of new treatments targeting drug‐resistant TB strains.

Vitamin in the Crosshairs: Targeting Pantothenate and Coenzyme A Biosynthesis for New Antituberculosis Agents

The Mycobactin Biosynthesis Pathway: A Prospective Therapeutic Target in the Battle against Tuberculosis

Unearthing phytochemicals as natural inhibitors for pantothenate synthetase in Mycobacterium tuberculosis: A computational approach

An Extensive Computational Investigation of Mycobacterium tuberculosis Pantothenate Synthetase Inhibitors from Diverse‐Lib Compounds Library

The pathogenic mechanism of Mycobacterium tuberculosis: implication for new drug development

Approaches for targeting the mycobactin biosynthesis pathway for novel anti-tubercular drug discovery: where we stand

A High-Throughput Screen against Pantothenate Synthetase (PanC) Identifies 3-Biphenyl-4-Cyanopyrrole-2-Carboxylic Acids as a New Class of Inhibitor with Activity against Mycobacterium tuberculosis

Amino Acid Biosynthesis Inhibitors in Tuberculosis Drug Discovery

Recent Advances in Antitubercular Compounds Targeting Mycolic Acid Biosynthesis and Transport

Mycobacterial β-carbonic anhydrases: Molecular biology, role in the pathogenesis of tuberculosis and inhibition studies

Reaction Intermediate Analogues As Bisubstrate Inhibitors of Pantothenate Synthetase

New Anti-Tuberculosis Drugs: Strategies, Sources and New Molecules

Opposing reactions in coenzyme A metabolism sensitize Mycobacterium tuberculosis to enzyme inhibition

Key Targets and Relevant Inhibitors for the Drug Discovery of Tuberculosis

Overcoming Mycobacterium Tuberculosis Through Small Molecule Inhibitors to Break Down Cell Wall Synthesis

Targeting the Histidine Pathway in Mycobacterium tuberculosis

The War against Tuberculosis: A Review of Natural Compounds and Their Derivatives

Highly Potent and Selective N-Aryl Oxamic Acid-Based Inhibitors for Mycobacterium Tuberculosis Protein Tyrosine Phosphatase B

New anti-tuberculosis agents amongst known drugs

Chemical Classes Presenting Novel Antituberculosis Agents Currently in Different Phases of Drug Development: A 2010–2020 Review

Dual-targeting GroEL/ES chaperonin and protein tyrosine phosphatase B (PtpB) inhibitors: A polypharmacology strategy for treating Mycobacterium tuberculosis infections